enzastaurin has been researched along with osimertinib in 1 studies
| Studies (enzastaurin) | Trials (enzastaurin) | Recent Studies (post-2010) (enzastaurin) | Studies (osimertinib) | Trials (osimertinib) | Recent Studies (post-2010) (osimertinib) |
|---|---|---|---|---|---|
| 188 | 52 | 99 | 1,315 | 134 | 1,282 |
| Protein | Taxonomy | enzastaurin (IC50) | osimertinib (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 1 | |
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | 3.98 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1858 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0274 | |
| Insulin receptor | Homo sapiens (human) | 0.912 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 3.26 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.0268 | |
| von Hippel-Lindau disease tumor suppressor | Homo sapiens (human) | 0.002 | |
| Histone deacetylase 4 | Homo sapiens (human) | 1 | |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | 0.0395 | |
| Epidermal growth factor receptor | Mus musculus (house mouse) | 0.081 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.57 | |
| Histone deacetylase 1 | Homo sapiens (human) | 1 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.033 | |
| Histone deacetylase 7 | Homo sapiens (human) | 1 | |
| Histone deacetylase 2 | Homo sapiens (human) | 1 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 1 | |
| Histone deacetylase 11 | Homo sapiens (human) | 1 | |
| Histone deacetylase 8 | Homo sapiens (human) | 1 | |
| Histone deacetylase 6 | Homo sapiens (human) | 1 | |
| Histone deacetylase 9 | Homo sapiens (human) | 1 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.177 | |
| Histone deacetylase 5 | Homo sapiens (human) | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
1 other study(ies) available for enzastaurin and osimertinib
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |